Ultrahuman has secured ₹100 crore in venture debt from Alteria Capital to accelerate its global expansion and product innovation even as it faces a legal ban on its ring sales in the U.S.
Glimpse:
The Bengaluru-based wearable health-tech firm is using the capital to deepen features in its ecosystem, strengthen software-led revenue, and expand into markets like Canada, Australia, and Germany. The debt raise comes at a time when Ultrahuman’s U.S. operations are under strain due to a ban on its smart rings.
Ultrahuman has raised ₹100 crore (around US$11.2 million) in venture debt from Alteria Capital. According to the company, this infusion of capital will help deepen innovation across its wearable ecosystem, strengthen software-led revenue, and accelerate global market expansion.
Mohit Kumar, CEO of Ultrahuman, said the company has built its business on “cost-disciplined growth and capital efficiency.” He added that this partnership with Alteria lets them scale during a critical growth season while remaining lean. Alteria Capital’s Vinod Murali commented that with rising consumer affluence, opportunities for health optimisation are “massive,” and Ultrahuman’s engineering-led approach is well-suited to tap into this trend.
Ultrahuman’s broader plan includes expanding its presence in international markets including Canada, Australia, and Germany as part of its aggressive scale-up strategy. The company also plans to invest in partnerships in sports and research, and to build out new product features and software capabilities.
However, this raise comes amid a challenging episode in the U.S.: Ultrahuman is reportedly grappling with a regulatory and patent dispute with Oura. Some reports suggest that the ban on ring imports could pressure its U.S. business, although Ultrahuman hopes its Texas manufacturing facility may help mitigate the impact.
“This capital allows us to double down on innovation even when the road is bumpy. We’re building for the future, not just chasing the next sale.”
By
HB Team
